Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Stoke Therapeutics (STOK) Research & Development (2022 - 2025)

Stoke Therapeutics (STOK) has 4 years of Research & Development data on record, last reported at $37.7 million in Q3 2025.

  • For Q3 2025, Research & Development rose 69.76% year-over-year to $37.7 million; the TTM value through Sep 2025 reached $119.6 million, up 36.76%, while the annual FY2024 figure was $89.1 million, 8.39% up from the prior year.
  • Research & Development reached $37.7 million in Q3 2025 per STOK's latest filing, up from $25.9 million in the prior quarter.
  • Across five years, Research & Development topped out at $37.7 million in Q3 2025 and bottomed at $18.3 million in Q1 2022.
  • Average Research & Development over 4 years is $23.0 million, with a median of $21.1 million recorded in 2024.
  • Peak YoY movement for Research & Development: grew 0.81% in 2023, then skyrocketed 69.76% in 2025.
  • A 4-year view of Research & Development shows it stood at $21.1 million in 2022, then grew by 3.41% to $21.8 million in 2023, then grew by 7.55% to $23.4 million in 2024, then soared by 60.94% to $37.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for Research & Development were $37.7 million in Q3 2025, $25.9 million in Q2 2025, and $32.7 million in Q1 2025.